The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Open accessAbstract
Breast cancer is a serious health problem worldwide, representing the second cause of death through malignancies among women in developed countries. Population, endogenous and exogenous hormones, and physiological, genetic and breast-related factors are involved in breast cancer pathogenesis. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) is a signaling pathway involved in cell proliferation, survival, invasion, migration, apoptosis, glucose metabolism and DNA repair. In breast tumors, PIK3CA somatic mutations have been reported, located in exon 9 and exon 20. Up to 40% of PIK3CA mutations are estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) -negative in primary and metastatic breast cancer. HER2 is overexpressed in 20–30% of breast cancers. HER1, HER2, HER3 and HER4 are membrane receptor tyrosine kinases involved in HER signaling to which various ligands can be attached, leading to PI3K/AKT activation. Currently, clinical studies evaluate inhibitors of the PI3K/AKT/mTOR axis. The main purpose of this review is to present general aspects of breast cancer, the components of the AKT signaling pathway, the factors that activate this protein kinase B, PI3K/AKT-breast cancer mutations, PI3K/AKT/mTOR-inhibitors, and the relationship between everolimus, temsirolimus and endocrine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Breast cancer statistics, 2019
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,114
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Mammographic Density and the Risk and Detection of Breast Cancer
Boyd, N. F., Guo, H., Martin, L. J., Sun, L., Stone, J., Fishell, E., Jong, R. A., Hislop, G., Chiarelli, A., Minkin, S., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062790 · Cited by 2,478
The GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A., & McCormick, F. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,333
Breast cancer statistics, 2013
DeSantis, C., Ma, J., Bryan, L., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21203 · Cited by 2,143
Ma, J., & Jemal, A. (2013) · Breast Cancer Metastasis and Drug Resistance · doi:10.1007/978-1-4614-5647-6_1 · Cited by 1,907
Breast cancer statistics, 2017, racial disparity in mortality by state
DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21412 · Cited by 1,879
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.606 · Cited by 1,793
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,508
Breast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Incidence and Mortality and Epidemiology of Breast Cancer in the World
Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.43 · Cited by 1,115
Collaborative Group on Hormonal Factors in Breast Cancer (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600596 · Cited by 1,082
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Benign Breast Disease and the Risk of Breast Cancer
Hartmann, L. C., Sellers, T. A., Frost, M. H., Lingle, W. L., Degnim, A. C., Ghosh, K., Vierkant, R. A., Maloney, S. D., Pankratz, V. S., Hillman, D. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044383 · Cited by 938
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
Tan, M.-H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2283 · Cited by 892
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
Diabetes mellitus and risk of breast cancer: A meta‐analysis
Larsson, S. C., Mantzoros, C. S., & Wolk, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22717 · Cited by 875
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Ras proteins: different signals from different locations
Hancock, J. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1105 · Cited by 756
Cancer statistics for African Americans, 2019
DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21555 · Cited by 743
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Endogenous Hormones and Breast Cancer Risk
Bernstein, L., & Ross, R. K. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036116 · Cited by 691
Akt in cancer: Mediator and more
Revathidevi, S., & Munirajan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.002 · Cited by 691
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., & Pogribny, I. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0021 · Cited by 635
Lahmann, P. H., Hoffmann, K., Allen, N., van Gils, C. H., Khaw, K., Tehard, B., Berrino, F., Tjønneland, A., Bigaard, J., Olsen, A., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20315 · Cited by 580
Breast Cancer Epidemiology and Risk Factors
ROJAS, K., & STUCKEY, A. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000239 · Cited by 576
McTiernan, A., Kooperberg, C., White, E., Wilcox, S., Coates, R., Adams-Campbell, L. L., Woods, N., & Ockene, J. (2003) · JAMA · doi:10.1001/jama.290.10.1331 · Cited by 568
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Gunter, M. J., Hoover, D. R., Yu, H., Wassertheil-Smoller, S., Rohan, T. E., Manson, J. E., Li, J., Ho, G. Y. F., Xue, X., Anderson, G. L., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn415 · Cited by 563
Oral Contraceptives and the Risk of Breast Cancer
Marchbanks, P. A., McDonald, J. A., Wilson, H. G., Folger, S. G., Mandel, M. G., Daling, J. R., Bernstein, L., Malone, K. E., Ursin, G., Strom, B. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013202 · Cited by 532
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
Giordano, S. H., Buzdar, A. U., & Hortobagyi, G. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00013 · Cited by 490
Colditz, G. A. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.10.950 · Cited by 487
Night work and breast cancer risk: A systematic review and meta-analysis
Megdal, S. P., Kroenke, C. H., Laden, F., Pukkala, E., & Schernhammer, E. S. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.010 · Cited by 482
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
PTEN and Myotubularin: Novel Phosphoinositide Phosphatases
Maehama, T., Taylor, G. S., & Dixon, J. E. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.247 · Cited by 461
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Oral contraceptives and the risk of breast cancer*
(2003) · Obstetrics & Gynecology · doi:10.1097/00006250-200304000-00031 · Cited by 431
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer Among Premenopausal Women
Eliassen, A. H., Missmer, S. A., Tworoger, S. S., Spiegelman, D., Barbieri, R. L., Dowsett, M., & Hankinson, S. E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj376 · Cited by 385
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez-Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M., González-Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó-Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 380
Reproductive Risk Factors in a Prospective Study of Breast Cancer: The Nurses' Health Study
Rosner, B., Colditz, G. A., & Willett, W. C. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117079 · Cited by 371
Endocrine resistance in breast cancer – An overview and update
Clarke, R., Tyson, J. J., & Dixon, J. M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.035 · Cited by 353
Incidence of Female Breast Cancer among Atomic Bomb Survivors, Hiroshima and Nagasaki, 1950–1990
Land, C. E., Tokunaga, M., Koyama, K., Soda, M., Preston, D. L., Nishimori, I., & Tokuoka, S. (2003) · Radiation Research · doi:10.1667/rr3082 · Cited by 347
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Serum insulin-like growth factor-I and breast cancer
Toniolo, P., Bruning, P. F., Akhmedkhanov, A., Bonfrer, J. M. G., Koenig, K. L., Lukanova, A., Shore, R. E., & Zeleniuch-Jacquotte, A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001201)88:5<828::aid-ijc22>3.0.co;2-8 · Cited by 341
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Physiological roles of PKB/Akt isoforms in development and disease
Dummler, B., & Hemmings, B. A. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350231 · Cited by 316
Lundqvist, A., Andersson, E., Ahlberg, I., Nilbert, M., & Gerdtham, U. (2016) · The European Journal of Public Health · doi:10.1093/eurpub/ckw070 · Cited by 309
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi352 · Cited by 307
An overview of mammographic density and its association with breast cancer
Nazari, S. S., & Mukherjee, P. (2018) · Breast Cancer · doi:10.1007/s12282-018-0857-5 · Cited by 298
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
Milk, Dairy Fat, Dietary Calcium, and Weight Gain: A Longitudinal Study of Adolescents
Berkey, C. S., Rockett, H. R. H., Willett, W. C., & Colditz, G. A. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.6.543 · Cited by 279
PI3K/Akt/mTOR inhibitors in breast cancer.
Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 276
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 259
Tamimi, R. M., Byrne, C., Colditz, G. A., & Hankinson, S. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm062 · Cited by 258
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
García-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer
Godet, I., & M. Gilkes, D. (2017) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000228 · Cited by 250
The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34
Backer, J. M. (2016) · Biochemical Journal · doi:10.1042/bcj20160170 · Cited by 238
New Strategies in Estrogen Receptor–Positive Breast Cancer
Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230
The melatonin hypothesis: electric power and breast cancer.
Stevens, R. G., & Davis, S. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104s1135 · Cited by 227
Xing, Y., Lin, N. U., Maurer, M. A., Chen, H., Mahvash, A., Sahin, A., Akcakanat, A., Li, Y., Abramson, V., Litton, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1154-8 · Cited by 220
Luo, J., Margolis, K. L., Wactawski-Wende, J., Horn, K., Messina, C., Stefanick, M. L., Tindle, H. A., Tong, E., & Rohan, T. E. (2011) · BMJ · doi:10.1136/bmj.d1016 · Cited by 219
Lochhead, P. A., Coghlan, M., Rice, S. Q. J., & Sutherland, C. (2001) · Diabetes · doi:10.2337/diabetes.50.5.937 · Cited by 219
Nurses' Health Study: Log-Incidence Mathematical Model of Breast Cancer Incidence
Rosner, B., & Colditz, G. A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.6.359 · Cited by 217
PIK3CA in cancer: The past 30 years
Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 216
Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer
Tworoger, S. S., Eliassen, A. H., Rosner, B., Sluss, P., & Hankinson, S. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1870 · Cited by 210
Patel, P., & Woodgett, J. R. (2017) · Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.11.011 · Cited by 210
Houghton, P. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1314 · Cited by 208
PIK3CA mutations in breast cancer are associated with poor outcome
Li, S. Y., Rong, M., Grieu, F., & Iacopetta, B. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9048-0 · Cited by 207
Yu, X., Long, Y. C., & Shen, H.-M. (2015) · Autophagy · doi:10.1080/15548627.2015.1043076 · Cited by 205
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
de Melo Gagliato, D., Leonardo Fontes Jardim, D., Marchesi, M. S. P., & Hortobagyi, G. N. (2016) · Oncotarget · doi:10.18632/oncotarget.7043 · Cited by 198
Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 190
Berchtold, D., & Walther, T. C. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-10-1001 · Cited by 189
PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 189
Sieri, S., Krogh, V., Ferrari, P., Berrino, F., Pala, V., Thiébaut, A. C., Tjønneland, A., Olsen, A., Overvad, K., Jakobsen, M. U., et al. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26090 · Cited by 185
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学:英文版 · Cited by 185
Akt/PKB: one kinase, many modifications
Risso, G., Blaustein, M., Pozzi, B., Mammi, P., & Srebrow, A. (2015) · Biochemical Journal · doi:10.1042/bj20150041 · Cited by 178
Braccini, L., Ciraolo, E., Campa, C. C., Perino, A., Longo, D. L., Tibolla, G., Pregnolato, M., Cao, Y., Tassone, B., Damilano, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8400 · Cited by 177
Epidemiology of Breast Cancer in Europe and Africa
Abdulrahman, G. O., & Rahman, G. A. (2012) · Journal of Cancer Epidemiology · doi:10.1155/2012/915610 · Cited by 173
Structure of small G proteins and their regulators.
Paduch, M., Jeleń, F., & Otlewski, J. (2001) · Acta Biochimica Polonica · doi:10.18388/abp.2001_3850 · Cited by 173
Molecular characterization and targeted therapeutic approaches in breast cancer
Toss, A., & Cristofanilli, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0560-9 · Cited by 170
Autophagy and endocrine resistance in breast cancer
Cook, K. L., Shajahan, A. N., & Clarke, R. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.111 · Cited by 170
The Role of Phosphoinositide 3-Kinase C2α in Insulin Signaling
Falasca, M., Hughes, W. E., Dominguez, V., Sala, G., Fostira, F., Fang, M. Q., Cazzolli, R., Shepherd, P. R., James, D. E., & Maffucci, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704357200 · Cited by 167
Meat consumption and risk of breast cancer in the UK Women's Cohort Study
Taylor, E. F., Burley, V. J., Greenwood, D. C., & Cade, J. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603689 · Cited by 163
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
Ruiz-Sáenz, A., Dreyer, C. A., Campbell, M. R., Steri, V., Gulizia, N., & Moasser, M. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0430 · Cited by 160
Lange, C. A., & Yee, D. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0112 · Cited by 148
Zardavas, D., Marvelde, L. T., Milne, R. L., Fumagalli, D., Fountzilas, G., Kotoula, V., Razis, E. D., Papaxoinis, G., Joensuu, H., Moynahan, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8301 · Cited by 148
Sobral‐Leite, M., Salomon, I., Opdam, M., Kruger, D. T., Beelen, K. J., van der Noort, V., van Vlierberghe, R. L. P., Blok, E. J., Giardiello, D., Sanders, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1176-2 · Cited by 147
Szymonowicz, K., Oeck, S., Malewicz, N. M., & Jendrossek, V. (2018) · Cancers · doi:10.3390/cancers10030078 · Cited by 145
Schettini, F., Buono, G., Cardalesi, C., Desideri, I., Placido, S. D., & Mastro, L. D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.012 · Cited by 144
The relationship of cancer of the female breast to artificial menopause and marital status
Lilienfeld, A. M. (1956) · Cancer · doi:10.1002/1097-0142(195609/10)9:5<927::aid-cncr2820090510>3.0.co;2-3 · Cited by 143
Roles of mTOR Signaling in Tissue Regeneration
Wei, X., Luo, L., & Chen, J.-Z. (2019) · Cells · doi:10.3390/cells8091075 · Cited by 143
Épidémiologie des cancers du sein
Sancho-Garnier, H., & Colonna, M. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.09.022 · Cited by 138
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K., Paganini‐Hill, A., Wan, P. C., & Pike, M. C. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200007000-00022 · Cited by 135
Metcalfe, K. A., Finch, A., Poll, A., Horsman, D. E., Kim‐Sing, C., Scott, J., Royer, R., Sun, P., & Narod, S. A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604830 · Cited by 135
Ghayad, S. E., Vendrell, J. A., Larbi, S. B., Dumontet, C., Bièche, I., & Cohen, P. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24750 · Cited by 131
Kim, Y.-J., Yoo, K., & Goodman, M. T. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.7.2857 · Cited by 131
Carbognin, L., Miglietta, F., Paris, I., & Dieci, M. V. (2019) · Cancers · doi:10.3390/cancers11091401 · Cited by 123
Dokken, B. B., Sloniger, J. A., & Henriksen, E. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00547.2004 · Cited by 120
Hatse, S., Lambrechts, D., Verstuyf, A., Smeets, A., Brouwers, B. A. H., Vandorpe, T., Brouckaert, O., Peuteman, G., Laenen, A., Verlinden, L., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs187 · Cited by 119
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0936 · Cited by 117
Biological mechanisms and clinical implications of endocrine resistance in breast cancer
Giuliano, M., Schiff, R., Osborne, C. K., & Trivedi, M. V. (2011) · The Breast · doi:10.1016/s0960-9776(11)70293-4 · Cited by 112
Incidence and Mortality of Breast Cancer and their Relationship to Development in Asia
Ghoncheh, M., Mohammadian-Hafshejani, A., & Salehiniya, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.14.6081 · Cited by 110
Ortega, A., Feinberg, D. M., Liang, Y., Rossa, C., & Graves, D. T. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2017019636 · Cited by 109
Getting the Akt Together: Guiding Intracellular Akt Activity by PI3K
Yudushkin, I. A. (2019) · Biomolecules · doi:10.3390/biom9020067 · Cited by 108
Henderson, T. O., Moskowitz, C. S., Chou, J. F., Bradbury, A. R., Neglia, J. P., Dang, C. T., Onel, K., Friedman, D. N., Bhatia, S., Strong, L. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3314 · Cited by 104
Cobain, E. F., Milliron, K. J., & Merajver, S. D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.001 · Cited by 102
Luqmani (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.942 · Cited by 99
Essential Role of Pten in Body Size Determination and Pancreatic β-Cell Homeostasis In Vivo
Nguyen, K.-T. T., Tajmir, P., Lin, C. H., Liadis, N., Zhu, X.-D., Eweida, M., Karaman, G., Cai, F., Wang, R., Kitamura, T., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00238-06 · Cited by 99
Romieu, I., Scoccianti, C., Chajès, V., de Batlle, J., Biessy, C., Dossus, L., Baglietto, L., Clavel‐Chapelon, F., Overvad, K., Olsen, A., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29469 · Cited by 95
Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
Kechagioglou, P., Papi, R. M., Provatopoulou, X., Kalogera, E., Papadimitriou, E., Grigoropoulos, P., Nonni, A., Zografos, G., Kyriakidis, D. A., & Gounaris, A. (2014) · PubMed · Cited by 95
Cavazzoni, A., Bonelli, M. A., Fumarola, C., Monica, S. L., Airoud, K., Bertoni, R., Alfieri, R. R., Galetti, M., Tramonti, S., Galvani, E., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.034 · Cited by 94
Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
Cretella, D., Digiacomo, G., Giovannetti, E., & Cavazzoni, A. (2019) · Cancers · doi:10.3390/cancers11091318 · Cited by 92
Schmid, P., Zaiss, M. R., Harper-Wynne, C. L., Ferreira, M., Dubey, S., Chan, S. Y. T., Makris, A., Nemsadze, G., Brunt, A. M., Küemmel, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2526 · Cited by 91
Regulation and modulation of PTEN activity
Naderali, E., Khaki, A. A., Rad, J. S., Alihemmati, A., Rahmati, M., & Charoudeh, H. N. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4321-6 · Cited by 86
Anderson, E. J., Mollon, L. E., Dean, J. L., Warholak, T. L., Aizer, A. A., Platt, E., Tang, D. H., & Davis, L. E. (2020) · International Journal of Breast Cancer · doi:10.1155/2020/3759179 · Cited by 86
Hoppe, R., Achinger-Kawecka, J., Winter, S., Fritz, P., Lo, W., Schroth, W., & Brauch, H. B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.145 · Cited by 85
Guo, W., Key, T. J., & REEVES, G. K. (2018) · International Journal of Cancer · doi:10.1002/ijc.31394 · Cited by 84
Phase II trial of temsirolimus in patients with metastatic breast cancer
Fleming, G. F., Ma, C. X., Huo, D., Sattar, H. A., Tretiakova, M., Li, L., Hahn, O. M., Olopade, F. O., Nanda, R., Hoffman, P. C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1910-7 · Cited by 82
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Dieci, M. V., Miglietta, F., Griguolo, G., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102064 · Cited by 82
Jordan, N., Dutkowski, C. M., Barrow, D., Mottram, H. J., Hutcheson, I. R., Nicholson, R. I., Guichard, S. M., & Gee, J. M. W. (2014) · Breast Cancer Research · doi:10.1186/bcr3604 · Cited by 79
Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Colditz, G. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.909s.11.2 · Cited by 79
Hurvitz, S. A., Dalenc, F., Campone, M., O’Regan, R. M., Tjan-Heijnen, V. C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H. R., Tan-Chiu, E., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2689-5 · Cited by 76
A Meta-analysis of the Association Between Physical Activity and Breast Cancer Mortality
Lee, J. (2018) · Cancer Nursing · doi:10.1097/ncc.0000000000000580 · Cited by 76
mLST8 Promotes mTOR-Mediated Tumor Progression
Kakumoto, K., Ikeda, J., Okada, M., Morii, E., & Oneyama, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119015 · Cited by 70
Serum Vitamin D and Risk of Breast Cancer within Five Years
O’Brien, K. M., Sandler, D. P., Taylor, J. A., & Weinberg, C. R. (2017) · Environmental Health Perspectives · doi:10.1289/ehp943 · Cited by 69
Wu, A. H., Stanczyk, F. Z., Seow, A., Lee, H.-P., & Yu, M. C. (2002) · PubMed · Cited by 67
Forkhead box O proteins: Crucial regulators of cancer EMT
Ma, Z., Xin, Z., Hu, W., Jiang, S., Yang, Z. P., Yan, X., Li, X., Yang, Y., & Chen, F. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.004 · Cited by 61
Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss
Maiese, K. (2017) · Current Neurovascular Research · doi:10.2174/1567202614666171116102911 · Cited by 55
Second primary breast cancer after Hodgkin's disease
Horwich, A., & Swerdlow, A. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601499 · Cited by 52
Chen, M.-J., Wu, W., Yen, A. M.-F., Fann, J. C. ‐., Chen, S. L. ‐., Chiu, S. Y., Chen, H.-H., & Chiou, S.-T. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.205 · Cited by 52
Breast cancer risk factors in south of Islamic Republic of Iran: a case-control study
Mahouri, K. H., Zahedani, M. D., & Zare, S. (2007) · Eastern Mediterranean Health Journal · doi:10.26719/2007.13.6.1265 · Cited by 51
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients
Deng, L., Zhu, X., Sun, Y., Wang, J., Zhong, X., Li, J., Hu, M., & Zheng, H. Y. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.598 · Cited by 48
Foxo transcription factors in T cell biology and tumor immunity
Luo, C. T., & Li, M. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.006 · Cited by 46
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham, J. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.961429 · Cited by 46
Sadler, T., Gavriil, M., Annable, T., Frost, P., Greenberger, L. M., & Zhang, Y. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01170 · Cited by 38
The MMP-2 -735 C Allele is a Risk Factor for Susceptibility to Breast Cancer
Yari, K., Rahimi, Z., Moradi, M. T., & Rahimi, Z. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.15.6199 · Cited by 36
Yi, Z., Ma, F., Liu, B., Guan, X., Li, L., Li, C., Qian, H., & Xu, B. (2019) · BMC Cancer · doi:10.1186/s12885-019-5668-3 · Cited by 36
Allaitement maternel et cancer du sein
Freund, C., Mirabel, L., Annane, K., & Mathelin, C. (2005) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2005.07.030 · Cited by 34
Seiler, M., Ray-Coquard, I. L., Melichar, B., Yardley, D. A., Wang, R. X., Dodion, P. F., & Lee, M. A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.008 · Cited by 33
Shi, J.-J., Chen, S.-M., Guo, C.-L., Li, Y., Ding, J., & Meng, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.181 · Cited by 33
Jeong, S. H., An, Y., Choi, J., Park, B., Kang, D., Lee, M. H., Han, W., Noh, D., Yoo, K., & Park, S. K. (2017) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.17.152 · Cited by 32
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
O'Regan, R. M., & Paplomata (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30349 · Cited by 30
Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis
Dwivedi, S., Purohit, P., Misra, R., Lingeswaran, M., Vishnoi, J. R., Pareek, P., Misra, S., & Sharma, P. (2019) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-019-0811-0 · Cited by 29
Bhattacharvva, G. S., Biswas, J., Singh, J., Singh, M., Govindbabu, K., Ranade, A. A., Malhotra, H., Parikh, P., Shahid, T., & Basu, S. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70115-0 · Cited by 27
Tong, J., Li, Z., Shi, J. C., Li, H., Wang, Y., Fu, L., & Liu, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097498 · Cited by 26
Magnusson, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1183 · Cited by 26
Hormonal contraceptives and breast cancer: Clinical data
Zolfaroli, I., Tarín, J. J., & Cano, A. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.03.058 · Cited by 26
Travail de nuit, travail posté : facteur de risque du cancer du sein ?
Benabu, J.-C., Stoll, F., Gonzalez, M., & Mathelin, C. (2015) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2015.10.004 · Cited by 25
Mahoney, R. E., Azpurua, J., & Eaton, B. A. (2016) · eLife · doi:10.7554/elife.16807 · Cited by 25
Induced abortion and breast cancer
Deng, Y., Xu, H., & Zeng, X. (2018) · Medicine · doi:10.1097/md.0000000000009613 · Cited by 21
Dai, Q., Liu, B., & Du, Y. (2009) · Frontiers of Medicine · doi:10.1007/s11684-009-0080-z · Cited by 19
Tabassum, I. (2016) · PubMed · doi:10.14456/apjcp.2016.84 · Cited by 18
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
Petrossian, K., Nguyen, D. M., Lo, C., Kanaya, N., Somlo, G., Cui, Y. X., Huang, C., & Chen, S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4779-x · Cited by 16
Molecular Biology of Breast Cancer
Aftimos, P. G., Azim, H. A., & Sotiriou, C. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00026-2 · Cited by 15
Bostner, J., Alayev, A., Berman, A. Y., Fornander, T., Nordenskjöld, B. A., Holz, M. K., & Stål, O. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4508-x · Cited by 15
Normal Weight Adiposity and Postmenopausal Breast Cancer Risk
Pimentel, I., Lohmann, A. E., & Goodwin, P. J. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5162 · Cited by 11
Cited by
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Advances in immunotherapy for triple-negative breast cancer
Liu, Y., Hu, Y., Xue, J., Li, J., Yi, J., Bu, J., Zhang, Z., Qiu, P., & Gu, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01850-7 · Cited by 337
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78
Revealing the Potency of Growth Factors in Bovine Colostrum
Yalçıntaş, Y. M., Duman, H., López, J. M. M., Portocarrero, A. C. M., Lombardo, M., Khallouki, F., Koch, W., Bordiga, M., El-Seedi, H., Raposo, A., et al. (2024) · Nutrients · doi:10.3390/nu16142359 · Cited by 31
“Binding to these receptors triggers the activation of critical intracellular signaling pathways, including PI3K/Akt and MAPK, and these pathways serve as molecular keys regulating cellular growth, survival, and metabolism (Table 2) (Figure 2) [91].”
Background
Metadata
- Authors
- Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-12-26
- Volume
- 22
- Issue
- 1
- Pages
- 173
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3113405673
- Cited by
- 845
- References
- 182
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.